Changing Course: A Pharmacist-Focused Approach to Improving Patient Outcomes in Multiple Sclerosis

Ebtesam Ahmed, PharmD
Published Online: Wednesday, October 17, 2012
Follow Pharmacy_Times:

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

Changing Course: A Pharmacist-Focused Approach to Improving Patient Outcomes in Multiple Sclerosis


Ebtesam Ahmed, PharmD
Assistant Clinical Professor
College of Pharmacy, St. John's University
Clinical Pharmacist Specialist
Department of Pain Medicine and Palliative Care
Beth Israel Medical Center
New York, NY

 



Ebtesam Ahmed, PharmD has no relevant financial relationships with commercial interests to disclose related to this activity.

Pharmacy Times Office of Continuing Professional Education (PTOCPE) Planning Staff

Judy V. Lum, MPA, and Elena Beyzarov, PharmD, have no relevant financial relationships with commercial interests to disclose related to this activity.

Pharmacy Times Editorial Staff

Jennifer Whartenby and David Allikas have no relevant financial relationships with commercial interests to disclose related to this activity.

PTOCPE uses an anonymous peer reviewer as part of content validation and conflict of interest resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose related to this activity.
 



Educational Objectives

Upon completion of this educational activity, participants should be able to:

  1. Examine the epidemiology, pathophysiology, and clinical progression of multiple sclerosis (MS).
  2. Evaluate current and emerging therapeutic strategies for slowing disease progression in patients with MS and their role in the treatment paradigm.
  3. Describe common adverse events associated with MS therapies and strategies for mitigating these side effects.
  4. Identify the role of the pharmacist in maximizing patient outcomes by improving adherence in patients with MS.

Target audience: Pharmacists
Type of activity: Knowledge
Release date: October 4, 2012
Expiration date: October 4, 2014
Estimated time to complete activity: 2 hours
Fee: This lesson is free online

Click here to view this activity.



Related Articles
The first FDA-approved “smart pill” documents medication adherence and physiologic response.
The FDA has approved alemtuzumab (Lemtrada) for the treatment of patients with relapsing forms of multiple sclerosis.
To ensure medication adherence among ethnically diverse elderly patients, senior care pharmacists must consider their cultural perspectives.
Dispensing generic hormonal therapies instead of their brand-name counterparts increases breast cancer patients’ life-saving medication adherence by 50%.
Latest Issues
$auto_registration$